A somatization comorbidity phenotype impacts response to therapy in rheumatoid arthritis: post-hoc results from the certolizumab pegol phase 4 PREDICT trial

Table 1 Patient baseline characteristics by SCP status^a

	+SCP (n = 313)	−SCP (n = 420)
Mean (SD), n unless otherwise stated
Randomized to assessment arm
RAPID3, n (% overall)	151 (48.2)	217 (51.7)
CDAI, n (% overall)	162 (51.8)	203 (48.3)
DAS28(ESR)	6.34 (1.07), 306	6.27 (1.07), 411
CDAI	41.41 (13.25), 307	39.30 (13.01), 416
RAPID3	16.76 (5.31), 308	15.56 (5.73), 415
TJC	16.82 (6.81), 308	15.08 (6.74), 416
SJC	12.12 (5.65), 308	12.26 (5.66), 416
PhGADA (VAS)^b	6.19 (1.83), 308	6.21 (1.78), 416
PtGADA (VAS)^b	6.21 (2.23), 308	5.74 (2.35), 416
Pain MDHAQ-PN (0–10 scale)	6.83 (2.07), 308	6.33 (2.16), 415
Physical function MDHAQ-FN (converted to 0–10 scale for RAPID3)	3.73 (1.82), 308	3.49 (1.92), 416

Full analysis set of the PREDICT trial. For these baseline values, some patients (<3% overall) were excluded due to prohibited concomitant medications affecting their assessments. Those with valid assessments at subsequent study visits were not excluded from the overall study
Abbreviations: SCP somatization comorbidity phenotype, ESR erythrocyte sedimentation rate, CDAI Clinical Disease Activity Index, DAS28 Disease Activity Score in 28 joints, MDHAQ Multidimensional Health Assessment Questionnaire, PhGADA Physician’s Global Assessment of Disease Activity, PtGADA Patient’s Global Assessment of Disease Activity, RAPID3 Routine Assessment of Patient Index Data 3, SJC swollen joint count, TJC tender joint count
^aCombining the RAPID3 and CDAI arms
^bVisual analog scale (0–100 mm converted to cm)

ISSN: 1478-6362